U.S. markets open in 8 hours 45 minutes

Merck & Co., Inc. (MRK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
76.61-0.62 (-0.80%)
At close: 4:02PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close77.23
Open76.74
Bid0.00 x 1300
Ask0.00 x 3000
Day's Range76.15 - 77.22
52 Week Range68.44 - 83.78
Volume16,350,342
Avg. Volume12,166,400
Market Cap193.981B
Beta (5Y Monthly)0.41
PE Ratio (TTM)27.67
EPS (TTM)2.77
Earnings DateJul 29, 2021
Forward Dividend & Yield2.60 (3.37%)
Ex-Dividend DateJun 14, 2021
1y Target Est93.02
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-17% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 10 Best Healthcare Stocks to Buy According to Hedge Funds
    Insider Monkey

    10 Best Healthcare Stocks to Buy According to Hedge Funds

    In this article, we will take a look at some of the best healthcare stocks to buy based on the data of over 860 hedge funds tracked by Insider Monkey. You can skip our detailed analysis of the healthcare industry and go directly to see 5 Best Healthcare Stocks to Buy According to Hedge Funds. […]

  • Yahoo Finance Video

    Affordable Care Act survives third Supreme Court challenge

    Andy Slavitt, former White House COVID-19 Response Team adviser, author of ‘PREVENTABLE: The Inside Story of How Leadership Failures, Politics, and Selfishness Doomed the U.S. Coronavirus Response’, joins Yahoo Finance to discuss the COVID-19 response in the U.S. and the Supreme court upholding the Affordable Care Act.

  • Biden Administration Devotes Over $3.2B For Development Of Oral Antiviral Therapies For COVID-19: CNBC
    Benzinga

    Biden Administration Devotes Over $3.2B For Development Of Oral Antiviral Therapies For COVID-19: CNBC

    Officials on Thursday announced that the Biden Administration plans to invest more than $3.2 billion in developing antiviral medicines to treat COVID-19 and other viruses with pandemic potential, reported CNBC. The new program, dubbed Antiviral Program for Pandemics – is a "whole-of-government effort" that will speed up clinical trials of promising drug candidates and develop next-generation treatments for COVID-19 and other viruses that could cause future pandemics," said White House chief medi